Today, empowerDX, a subsidiary of Eurofins (Paris:ERF), launched PFAS Exposure™ in the United States, the first consumer home test to determine the levels of perfluorinated substances (PerFluoroAlkyl Substances, PFAS) in the blood of person and measure 47 of the compounds PFAS, “eternal chemicals”.
Per- and polyfluoroalkyl substances (Per- and Polyfluorinated Alkyl Substances, (PFAS), such as perfluorooctane acid (PerFluoro-Octan Acid, PFOA) and perfluorooctane sulfonic acid (PerFluor-Octan Sulfonic acid, PFOS), called ” eternal chemicals”, are characteristically resistant to natural breakdown in the environment and in human bodies. The US Centers for Disease Control and Prevention (CDC) reports that exposure to these chemicals can have adverse health effects, causing, for example, cancer, thyroid disorders, immune system dysfunction, high cholesterol, respiratory disease, and reduced fertility. report from the CDC’s National Health and Nutrition Examination Survey (NHANES) indicates that perfluorides are present in the blood of 97% of Americans.
The identification of PFAS through blood tests marks an important step. PFAS Exposure™, developed by environmental testing companies Eurofins and their research partners, and launched in the United States by empowerDX, is a self-administered sampling kit, the first of its kind, using a simple tip swab on point. To date, blood screening for PFAS has relied on serum as an estimate of all blood and has required a blood draw by a health care practitioner. Eurofins PFAS Exposure™ Collection Kits are an all-in-one solution that includes collection and transport essentials, allowing participants to self-collect samples at home or at work, and send them directly to the laboratory.
The PFAS Exposure Kit is available in the United States through empowerDX, Eurofins’ home health testing business. The kits can be purchased online at a price of 399 USD and are sent directly to the customer’s home or workplace.
For more information, please visit this website.
About Eurofins – the world leader in bioanalysis
Eurofins tests for life. With more than 55,000 employees in a network of 900 laboratories in more than 50 countries, Eurofins companies offer a portfolio of more than 200,000 analytical methods.
Eurofins shares are listed on Euronext Paris.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220121005286/en/